Investor Presentaiton
SELECT TRIALS - EARLY PHASE IMMUNOLOGY
Lilly
Molecule
Study
Indication*
Title
Phase Patients
Primary Outcome**
Primary
Completion
Completion
Peresolimab NCT05516758
Rheumatoid
Arthritis
A Study of Peresolimab (LY3462817) in Participants
With Moderately-to-Severely Active Rheumatoid
Arthritis (RESOLUTION-1)
2
420
BTLA MAB
Agonist
NCT05123586
Systemic Lupus
Erythematosus
A IMMA Master Protocol: A Study of LY3361237 in
Participants With at Least Moderately Active
Systemic Lupus Erythematosus
2
90
Percentage of Participants Achieving American
College of Rheumatology (ACR) 20
Percentage of Participants with Arthritis and/or Rash
at Baseline Who Achieve Remission of Arthritis
and/or Rash
Nov 2023 Jan 2025
Jan 2024 Apr 2024
Ucenprubart
(CD200R MAB NCT05911841
Agonist)
RIPK1
Inhibitor
Atopic
Dermatitis
A Study of LY3454738 in the Treatment of Adult
Participants With Moderate-to-Severe Atopic
2
260
Percentage of Participants Achieving Eczema Area
and Severity Index (EASI) 75
Sep 2024 Jul 2025
Dermatitis
NCT05848258
Arthritis
Rheumatoid An Adaptive Phase 2a/2b Study of LY3871801 in Adult
Participants With Rheumatoid Arthritis
2
380
hsCRP)
GITR
Antagonist NCT05486208 Healthy
Antibody
A Study of LY3844583 in Healthy Participants and
Participants With Atopic Dermatitis
1
86
CD19
NCT05042310 Healthy
A Study of LY3541860 in Healthy Japanese and Non-
Japanese Participants
1
84
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
2023 Q2 EARNINGS
Phase 2a: Change from Baseline in Disease Activity
Score high-sensitivity C-reactive protein (DAS28- Feb 2026 Jul 2026
Number of Participants with One or More Adverse
Events (AEs), Treatment Emergent Adverse Events
(TEAEs) and Serious Adverse Event(s) (SAEs)
Considered by the Investigator to be Related to Study
Drug Administration
Number of Participants with One or More Treatment
Emergent Adverse Events (TEAEs) and Serious
Adverse Event(s) (SAEs) Considered by the
Investigator to be Related to Study Drug
Administration
Jan 2024 Jan 2024
Jun 2024 Jun 2024
Source: clinicaltrials.gov, July 27, 2023
54View entire presentation